<DOC>
	<DOCNO>NCT00001502</DOCNO>
	<brief_summary>The presence highly selective blood-brain barrier ( BBB ) level brain capillary endothelium prevents chemotherapeutic agent attain therapeutic concentration target site . RMP-7 synthetic bradykinin analog specifically bind B2 receptor express brain capillary endothelial cell preferentially increase capillary permeability within CNS tumor . Carboplatin anticancer agent preclinical clinical antitumor activity variety brain tumor . A pediatric phase I trial combination RMP-7 carboplatin conduct determine maximum tolerate dose RMP-7 child refractory brain tumor .</brief_summary>
	<brief_title>A Pediatric Phase I Trial RMP-7 Carboplatin Brain Tumors</brief_title>
	<detailed_description>The presence highly selective blood-brain barrier ( BBB ) level brain capillary endothelium prevents chemotherapeutic agent attain therapeutic concentration target site . RMP-7 synthetic bradykinin analog specifically bind B2 receptor express brain capillary endothelial cell preferentially increase capillary permeability within CNS tumor . Carboplatin anticancer agent preclinical clinical antitumor activity variety brain tumor . A pediatric phase I trial combination RMP-7 carboplatin conduct determine maximum tolerate dose RMP-7 child refractory brain tumor .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm brain tumor include limited following : Anaplastic astrocytoma , Glioblastoma multiforme , Lowgrade glioma , Ependymoma , Medulloblastoma , Pineal tumor , Chiasmal glioma , Craniopharyngioma , Brain stem glioma ( requirement histologic diagnosis may waive ) . Disease refractory standard therapy standard chemotherapy exist ineligible potential curative surgery radiotherapy . Measurable evaluable disease radiographic study evidence progression prior chemotherapy radiotherapy persistent disease surgery . PRIOR/CURRENT THERAPY : See Disease Characteristics At least 6 month since carboplatin . At least 3 week since myelosuppressive therapy . Patients receive stem cell bone marrow rescue nitrosourea therapy eligible 3 week recover hematologic toxicity prior therapy . Concurrent steroid allow dose stable least 2 week prior entry . Recovered toxic effect prior therapy . PATIENT CHARACTERISTICS : Age : 21 . Performance status : ECOG 02 . Life expectancy : At least 8 week . HEMATOLOGIC : Absolute granulocyte count great 1,500/mm ( 3 ) . Platelet count great 100,000/mm ( 3 ) ( least 75,000/mm ( 3 ) patient prior bone marrow transplantation craniospinal irradiation ) . Hemoglobin great 8.0 g/dL . HEPATIC : Bilirubin great 2 time normal . ALT great 2 time normal . RENAL : Creatinine within normal limit age follow : Age ( year ) Creatinine ( mg/dL ) : Younger 5 great 1.2 ; 510 great 1.5 ; 1015 great 1.8 ; Older 15 great 2.4 . OTHER : No significant systemic illness . No pregnant nursing woman . Negative pregnancy test require fertile woman . Effective contraception require fertile patient . Durable power attorney require patient 1821 year age .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2000</verification_date>
	<keyword>Blood-Brain Barrier</keyword>
	<keyword>Bradykinin</keyword>
	<keyword>Children</keyword>
	<keyword>Glioma</keyword>
	<keyword>Medulloblastoma</keyword>
</DOC>